Autolus Therapeutics (AUTL) Accumulated Expenses (2017 - 2026)

Autolus Therapeutics (AUTL) has 9 years of Accumulated Expenses data on file, last reported at $55.8 million in Q4 2025.

• Quarterly Accumulated Expenses rose 6.73% year-over-year to $55.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $55.8 million (up 6.73% YoY) and the FY2025 annual result came in at $55.8 million, up 6.73% from the prior year.
• Accumulated Expenses advanced to $55.8 million in Q4 2025, from $52.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $55.8 million in Q4 2025 to a low of $23.2 million in Q2 2021.
• A 5-year average of $37.5 million and a median of $35.1 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2021 — Accumulated Expenses declined 14.81% — and 2022, when it surged 72.38%.
• Tracing AUTL's Accumulated Expenses over 5 years: stood at $23.7 million in 2021, then surged by 72.38% to $40.8 million in 2022, then declined by 2.98% to $39.6 million in 2023, then surged by 32.07% to $52.3 million in 2024, then advanced by 6.73% to $55.8 million in 2025.
• The last three Accumulated Expenses figures came in at $55.8 million (Q4 2025), $52.3 million (Q3 2025), and $51.4 million (Q2 2025), per Business Quant data.